| Literature DB >> 33293788 |
Jade Y Moon1,2, John B Miller1,2, Raviv Katz2, Thong Ta1, Colleen Szypko1, Itika Garg1,2, Alice C Lorch1, Matthew F Gardiner1, Grayson W Armstrong1.
Abstract
PURPOSE: During the COVID-19 pandemic, there is growing concern that patients are forgoing necessary care. Emergency departments (ED) represent an important site of eye care. We analyzed patterns of ED visits at an eye-specific ED since the declaration of the public health crisis.Entities:
Keywords: COVID-19; epidemiology; eye-specific emergency department; medical services; urgent ophthalmic diagnoses
Year: 2020 PMID: 33293788 PMCID: PMC7718995 DOI: 10.2147/OPTH.S285223
Source DB: PubMed Journal: Clin Ophthalmol ISSN: 1177-5467
Figure 1Timeline of announcements of public health recommendations regarding COVID-19 in Massachusetts and in the United States between March 1st, 2020 and April 30th, 2020 overlaid on graph of number of cumulative confirmed cases of COVID-19 in Massachusetts during the same time period (solid line) and number of daily new cases of COVID-19 in Massachusetts during the same period (dashed line).
Figure 2Boxplot of the average number of daily visits in each half-month block during the study period in 2018, 2019, and 2020.
Demographic Information
| 2018 | 2019 | 2020 | P-value ( | ||
|---|---|---|---|---|---|
| Age | Mean Age (SD) | 48.70 (19.83) | 48.22 (20.24) | 50.06 (18.86) | 0.002*, 0.03* |
| Gender | Male (%) | 1103 (46%) | 1215 (46%) | 830 (49%) | 0.107 |
| Female (%) | 1323 (54%) | 1401 (54%) | 872 (51%) | 0.107 | |
| Race | White (%) | 1684 (69%) | 1810 (69%) | 1160 (68%) | 0.668 |
| Black (%) | 256 (11%) | 260 (10%) | 160 (9%) | 0.471 | |
| Asian (%) | 164 (7%) | 161 (6%) | 67 (4%) | < 0.001* | |
| Hispanic (%) | 31 (1%) | 14 (0.5%) | 18 (1%) | 0.019* | |
| Native Americans (%) | 6 (0.2%) | 5 (0.2%) | 1 (0.1%) | 0.360 | |
| Other (%) | 234 (10%) | 257 (10%) | 182 (11%) | 0.503 | |
| Declined (%) | 51 (2%) | 110 (4%) | 114 (7%) | 0.457 |
Note: *p <0.05.
Frequency and Prevalence Ratios of Diagnostic Groups. List of top 5 primary diagnostic groups that presented to the MEE ED between March 1st and April 30th in 2018, 2019, and 2020 with the corresponding number of presentations in parentheses. Analysis was performed for the entire study period as well as for the four blocks of each year. Visual disturbances was a diagnostic group that appeared in the top five diagnostic groups in many blocks across the years. It included visual disturbances such as aura, flashes, floaters, blurred vision, and visual field defects.
| Hordeolum/chalazion (186) | Hordeolum/chalazion (36) | Injury of conjunctiva and corneal abrasion without foreign body (47) | Hordeolum/chalazion (54) | Hordeolum/chalazion (50) |
| Injury of conjunctiva and corneal abrasion without foreign body (151) | Injury of conjunctiva and corneal abrasion without foreign body (33) | Hordeolum/chalazion (46) | Injury of conjunctiva and corneal abrasion without foreign body (43) | Foreign body (41) |
| Keratitis (118) | Vitreous degeneration (32) | Keratitis (36) | Foreign body (29) | Keratitis (35) |
| Foreign body (108) | Keratitis (21) | Retinal detachment (24) | Visual disturbances (28) | Injury of conjunctiva and corneal abrasion without foreign body (28) |
| Vitreous degeneration (105) | Viral conjunctivitis (21) | Visual disturbances (23) | Vitreous degeneration (28) | Visual disturbances (28) |
| Hordeolum/chalazion (178) | Hordeolum/chalazion (52) | Injury of conjunctiva and corneal abrasion without foreign body (48) | Foreign body (44) | Vitreous degeneration (43) |
| Injury of conjunctiva and corneal abrasion without foreign body (155) | Injury of conjunctiva and corneal abrasion without foreign body (37) | Hordeolum/chalazion (45) | Hordeolum/chalazion (40) | Hordeolum/chalazion (41) |
| Foreign body (142) | Visual disturbances (32) | Foreign body (37) | Injury of conjunctiva and corneal abrasion without foreign body (34) | Injury of conjunctiva and corneal abrasion without foreign body (36) |
| Vitreous degeneration (112) | Foreign body (31) | Keratitis (27) | Vitreous degeneration (29) | Foreign body (30) |
| Visual disturbances (111) | Ocular pain (26) | Visual disturbances (26) | Visual disturbances (27) | Lacrimal gland dysfunction (27) |
| Vitreous degeneration (131) | Foreign body (45) | Injury of conjunctiva and corneal abrasion without foreign body (30) | Vitreous degeneration (31) | Vitreous degeneration (43) |
| Foreign body (118) | Hordeolum/chalazion (45) | Vitreous degeneration (28) | Foreign body (23) | Foreign body (28) |
| Injury of conjunctiva and corneal abrasion without foreign body (110) | Injury of conjunctiva and corneal abrasion without foreign body (34) | Hordeolum/chalazion (26) | Injury of conjunctiva and corneal abrasion without foreign body (23) | Injury of conjunctiva and corneal abrasion without foreign body (23) |
| Hordeolum/chalazion (109) | Vitreous degeneration (29) | Foreign body (22) | Hordeolum/chalazion (18) | Keratitis (21) |
| Retinal detachment (70) | Visual disturbances (25) | Retinal detachment (20) | Retinal detachment (10) | Hordeolum/chalazion (20) |
Prevalence Ratios of Diagnostic Groups. Diagnostic groups that are more prevalent in 2020 compared to prior years, as indicated by prevalence ratios greater than 1.00.
| Diagnosis | PR | 95% CI |
|---|---|---|
| Contusion of eyeball | 10.37 | (2.16, 49.86) |
| Benign intracranial hypertension | 5.92 | (1.09, 32.32) |
| Toxic exposure | 2.33 | (1.34, 4.06) |
| Laceration of eyelid | 2.80 | (1.45, 5.42) |
| Amaurosis fugax | 2.09 | (1.01,4.37) |
| Retinal vascular occlusion | 1.95 | (1.15, 3.28) |
| Vitreous degeneration | 1.79 | (1.45, 2.21) |
| Retinal detachments | 1.41 | (1.07,1.87) |
| Foreign body | 1.40 | (1.13, 1.73) |
Prevalence Ratios of Diagnostic Groups. Diagnostic groups that are less prevalent in 2020 compared to prior years, as indicated by prevalence ratios less than 1.00.
| Diagnosis | PR | 95% CI |
|---|---|---|
| Contact lens related disorder (excluding keratitis) | 0.27 | (0.11, 0.68) |
| Eyelid disorder | 0.32 | (0.17, 0.59) |
| Allergic conjunctivitis | 0.38 | (0.15, 0.98) |
| Vitreous opacities | 0.55 | (0.34, 0.88) |
Figure 3Days to follow up for patients who received follow up care < 31 days since their ED visit in 2018, 2019, and 2020.